{"id":"NCT01181479","sponsor":"Agile Therapeutics","briefTitle":"Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System","officialTitle":"Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2011-12","completion":"2012-03","firstPosted":"2010-08-13","resultsPosted":"2018-07-03","lastUpdate":"2018-07-03"},"enrollment":1504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"AG200-15 (cycles 1-13)","otherNames":["transdermal patch"]},{"type":"DRUG","name":"Lessina crossover to AG200-15","otherNames":["hormonal oral contraception and transdermal patch"]}],"arms":[{"label":"AG200-15 (cycles 1-13)","type":"EXPERIMENTAL"},{"label":"Lessina crossover to AG200-15","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.","primaryOutcome":{"measure":"Pregnancy","timeFrame":"AG200-15: 6 months; Lessina: 6 months; AG200-15: 1 year","effectByArm":[{"arm":"AG200-15 for Cycle 7-13","deltaMin":5.41,"sd":null},{"arm":"Lessina","deltaMin":6.67,"sd":null},{"arm":"AG200-15 for Cycle 1-13","deltaMin":6.43,"sd":null}],"pValues":[]},"eligibility":{"minAge":"17 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":80,"countries":["United States"]},"refs":{"pmids":["25586864","25582984","24402597"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":1273},"commonTop":["Cervical Dysplasia","Nasopharyngitis","Nausea","Headache","Upper respiratory tract infection"]}}